Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Table 3
Ranking for all the outcomes of the interventions included at 12 or 16 weeks in the network meta-analysis.
Interventions
PASI 75
PASI 100
sPGA 0/1 or IGA 0/1 or PGA 0/1
AEs
sAEs
Discontinuations due to AEs
SUCRA (%)
PrBest
MeanRank
SUCRA (%)
PrBest
MeanRank
SUCRA (%)
PrBest
MeanRank
SUCRA (%)
PrHighest risk
MeanRank
SUCRA (%)
PrHighest risk
MeanRank
SUCRA (%)
PrHighest risk
MeanRank
Brodalumab 140 mg
22.8
0.0
11.0
63.4
0.5
5.8
32.0
0.0
9.8
38.1
0.0
9.0
38.4
0.1
9.0
54.2
0.6
7.0
Brodalumab 210 mg
62.5
0.3
5.9
85.0
28.4
2.9
65.4
0.1
5.5
23.7
0.0
10.9
63.9
3.8
5.7
63.0
0.9
5.8
Guselkumab 100 mg
28.5
0.0
10.3
61.4
6.0
6.0
31.4
0.0
9.9
63.4
1.3
5.8
49.4
3.3
7.6
32.1
0.2
9.8
Guselkumab 50 mg
38.7
0.4
9.0
55.9
4.3
6.7
33.4
0.0
9.7
76.2
30.1
4.1
25.9
3.5
10.6
84.6
36.7
3.0
Ixekizumab 80 mg Q2W
93.0
53.4
1.9
83.3
32.7
3.2
86.5
13.3
2.8
7.5
0.0
13.0
50.8
3.1
7.4
14.8
0.0
12.1
Ixekizumab 80 mg Q4W
81.5
0.5
3.4
76.8
12.9
4.0
75.7
0.0
4.2
4.5
0.0
13.4
27.5
0.5
10.4
10.7
0.0
12.6
Placebo
0.0
0.0
14.0
0.0
0.0
14.0
0.0
0.0
14.0
67.3
0.0
5.3
59.4
0.1
6.3
39.7
0.0
8.8
Risankizumab 150 mg
62.3
0.4
5.9
71.3
6.4
4.7
66.7
0.4
5.3
67.6
5.3
5.2
92.8
61.5
1.9
92.6
53.2
2.0
Secukinumab 150 mg
73.5
0.0
4.4
31
0.1
10.0
85.7
0.0
2.9
22.7
0.0
11.0
30.7
0.4
10.0
43.5
0.2
8.4
Secukinumab 300 mg
89.9
43.1
2.3
62.4
8.3
5.9
98.1
86.0
1.3
33.9
0.0
9.6
35.6
0.9
9.4
42.2
0.1
8.5
Tildrakizumab 100 mg
33.2
0.2
9.7
21.9
0.4
11.2
22.3
0.0
11.1
88.8
27.9
2.5
70.8
18.9
4.8
58.6
4.5
6.4
Tildrakizumab 200 mg
42.2
1.7
8.5
20.0
0.0
11.4
34.7
0.2
9.5
90.2
31.3
2.3
41.1
1.2
8.7
35.4
0.4
9.4
Ustekinumab 45 mg
27.4
0.0
10.4
33.1
0.0
9.7
25.4
0.0
10.7
41.0
0.0
8.7
61.1
0.6
6.1
79.0
3.0
3.7
Ustekinumab 90 mg
44.5
0.0
8.2
34.5
0.0
9.5
42.8
0.0
8.4
75.2
4.1
4.2
52.5
2.1
7.2
49.7
0.2
7.5
SUCRA: surface under the cumulative ranking; PrBest: probability of best treatment; PrHighest risk: probability of the highest risk of AEs; PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events; Q2W: every 2 weeks; Q4W: every 4 weeks.